VolitionRx Limited (NYSE:VNRX) Forecasted to Post Q2 2024 Earnings of ($0.09) Per Share

VolitionRx Limited (NYSE:VNRX) – Investment analysts at Zacks Small Cap upped their Q2 2024 EPS estimates for VolitionRx in a research report issued to clients and investors on Tuesday, June 25th. Zacks Small Cap analyst S. Ralston now forecasts that the company will earn ($0.09) per share for the quarter, up from their previous forecast of ($0.10). The consensus estimate for VolitionRx’s current full-year earnings is ($0.34) per share. Zacks Small Cap also issued estimates for VolitionRx’s Q3 2024 earnings at ($0.07) EPS, Q4 2024 earnings at ($0.05) EPS and FY2024 earnings at ($0.29) EPS.

VolitionRx (NYSE:VNRX) last posted its earnings results on Monday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. The company had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $0.27 million.

A number of other research analysts have also issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $2.50 target price on shares of VolitionRx in a report on Thursday, May 16th. StockNews.com assumed coverage on shares of VolitionRx in a research note on Friday, June 21st. They set a “sell” rating on the stock.

VolitionRx Stock Up 3.4 %

Shares of NYSE:VNRX opened at $0.63 on Thursday. The company has a market capitalization of $52.32 million, a P/E ratio of -1.37 and a beta of 1.16. VolitionRx has a 52-week low of $0.55 and a 52-week high of $1.55. The stock’s fifty day simple moving average is $0.74 and its 200-day simple moving average is $0.84.

Institutional Trading of VolitionRx

An institutional investor recently bought a new position in VolitionRx stock. Silverberg Bernstein Capital Management LLC bought a new position in VolitionRx Limited (NYSE:VNRX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned about 0.19% of VolitionRx as of its most recent filing with the Securities and Exchange Commission (SEC). 8.09% of the stock is owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.